Human cytokine autoantibodies Characteristics, test procedures and possible physiological and clinical significance

APMIS, Supplement

Volumn 104, Issue 59, 1996, Pages

  Hansen, Morten Bagge ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645461078     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (258)

1. Abe, Y., Horiuchi, A., Miyake, M. & Kimura, S.: Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 139: 5-20, 1994.
2. Akira, S. & Kishimoto, T.: IL-6 and NF-IL6 in acutephase response and viral infection. Immunol. Rev. 727: 25-50, 1992.
3. Akira, S., Taga, T. & Kishimoto, T.: Interleukin-6 in biology and medicine. Adv. Immunol. 54: 1-78, 1993.
4. Akira, S., Nishio, Y., Inaue, M., Wang, X. J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M. & Kishimoto, T.: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71, 1994.
5. Almeida, G. D., Porada, C. D., St-Jeor, S. & Ascensao, J. L.: Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood 83: 370-376, 1994.
6. Altman, F.: Tetrazolium Salts and Formazans. Progr. Histochem. Cytochem. 9: 1-52, 1976.
7. Antonelli, G., Currenti, M., Turriziani, O. & Dianzani, F.: Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163: 882-885, 1991.
8. Antonelli, G. & Dianzani, F.: Antibodies to interferon alpha in patients. Arch. Virol. Suppl 8: 271-277, 1993.
9. Arend, W. P.: Interleukin-1 receptor antagonist. Adv. Immunol. 54: 167-227, 1993.
10. Arend, W. P. & Dayer, J. M.: Naturally occurring inhibitors of cytokines. In: Davies, M. E. & Dingle, J. T. (eds.), The handbook of immunopharmacology. Immunopharmacology of joints and connective tissue. N.Y.: Academic Press Limited., pp. 129-149, 1994.
11. Aston, R., Cowden, W. B. & Ada, G. L.: Antibody-mediated enhancement of hormone activity. Mol. Immunol. 26: 435-466, 1989.
12. Anlitzky, W, E., Peschel, C., Despres, D., Aman, J., Trautman, P., Tilg, H., Rudolf, G., Huttmann, H., Obermeier, J., Herold, M., et al.: Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronicphase chronic myelogenous leukemia. Ann. Hematol. 67: 205-211, 1993.
13. Avrameas. S.: Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 12: 154-159, 1991.
14. Avrameas, S. & Ternynck, T.: The natural autoantibodies system: between hypotheses and facts. Mol. Immunol. 30: 1133-1142, 1993.
15. Bagby, G. J., Plessala, K. J., Wilson, L. A., Thompson, J. J. & Nelson, S.: Divergent efficacy of anti-body to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J. Infect. Dis. 163: 83-88, 1991.
16. Barut, B., Chauhan, D., Uchiyama, H. & Anderson, K. C.: Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J. Clin. Invest. 92: 2346-2352, 1993.
17. Bataille, R., Zhang, X. G., Wijdenes, J., Sched, J. F. & Klein, B.: Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. Med. Oncol. Tumor Pharmacother. 10: 185-188, 1993.
18. Beck, J. T., Hsu, S. M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D., Hay den, K., Jaganna th, S. & Barlogie, B.: Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330: 602-605, 1994.
19. Bekisz, J. B., zur-Nedden. D. L., Enterline, J. C. & Zoon, K. C.: Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia. J. Interferon Res. 9 Suppl 1: S1-S7, 1989.
20. Bendtzen, K.: Some physicochemical properties of human leucocyte migration inhibitory factor (LIF). Acta Pathol. Microbiol. Scand. C. 84C: 471-476, 1976.
21. Bendtzen, K.: Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol. Lett. 19: 183-191, 1988.
22. Bendtzen, K.: Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases. Autoimmunity 2: 177-189, 1989.
23. Bendtzen, K., Svenson, M., Fomsgaard, A. & Poulsen, L. K.: Native inhibitors (autoantibodies) of IL-1 alpha and TNF. Immunol. Today 10: 222, 1989.
24. Bendtzen, K., Svenson, At., Fomsgaard, A., Poulsen, L. K. & Hansen, M.B.: Auto-antibodies to IL-1α and TNFcc in normal individuals and in infectious and immunoinflammatory disorders. Prog. Leuk. Biol. 10B: 447-452, 1990a.
25. Bendtzen, K., Svenson, M., Jonsson, K & Hippe, E: Autoantibodies to cytokines-friends or foes? Immunol. Today 11: 167-169, 1990b.
26. Bendtzen, K., Hansen, M. B., Diamant, M., Heegaard, P. & Svenson, M.: Cytokine regulation during inflammation: modulation by autoantibodies and fever. In: Bartfai, T. & Ottoson, D. (eds.), Neuro-Immunology of fever. Pergamon Press., pp. 215-224, 1991.
27. Bendtzen, K., Hansen, M. B. & Svenson, M.: Immunoinflammatory mediators (cytokines) in trauma. Natural regulation and intervention with systemic complications. In: Bonis, L. C., Lassen, M. R. & Bergqitist, D. (eds.), The traumatized patient with special reference to systemic complications. Aalborg: pp. 135-144, 1992.
28. Bendtzen, K., Hansen, M. B. & Srenson, M.: Modulation of inflammatory cytokines by a receptor antagonist, autoantibodies, and fever. In: Goldstein, A. L. & Garaci, G. (eds.), Combination Therapies 2. N.Y.: Plenum Press., pp. 123-134, 1993a.
29. Bendtzen, K., Svenson, M. & Hansen, M. B.: Autoantibodies to cytokines in IVIG. J. Rheumatol. 20: 12: 2176-2177, 1993b.
30. Bendtzen, K., Hansen, M. B., Diamant, M., Ross, C. & Svenson, M.: Naturally occurring autoantibodies to IL-1α, IL-6, IL-10 and IFNα. J. Interferon. Res. 14: 157-158, 1994a.
31. Bendtzen, K.: Cytokines and natural regulators of cytokines. Immunol. Lett. 43: 111-123, 1994b.
32. Berdy, S. S. & Bloch, K. J.: Schnitzler's syndrome: a broader clinical spectrum. J. Allergy Clin. Immunol. 87: 849-854, 1991.
33. Berg, K., Hansen, M. B. & Nielsen, S. E.: A new sensitive bioassay for precise quantification of interferon activity as measured via the mitochondrial dehydrogenase function in cells (MTT-method). APMIS 98: 156-162, 1990.
34. Bermudez, L. E. & Champsi, J.: Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect. Immun. 61: 3093-3097, 1993.
35. Beutler, B., Milsark, I. W. & Cerami, A. C.: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871, 1985.
36. Billiau, A., Heremans, H., Vandekerckhove, F. & Dillen, C.: Anti-interferon-gamma antibody protects mice against the generalized Shwartzman reaction. Eur. J. Immunol. 17: 1851-1854, 1987.
37. Bocci, V.: What is the function of autoantibodies to cytokines? Immunol. Today 11: 230-231, 1990.
38. Bocci, V.: What roles have anti-interferon antibodies in physiology and pathology? Res. Clin. Lab. 27: 79-84, 1991.
39. Bolin, DR.: Vasoactive intestinal peptide: role of calmodulin and catalytic antibodies. Neurochem. Int. 23: 221-227, 1993.
40. Bost, K. L., Halm, B. H., Saag, M. S., Shaw, G. M., Weigent, D. A. & Blalock, J. E.: Individuals infected with HIV possess antibodies against IL-2. Immunology 65: 611-615, 1988.
41. Boyle, P., Lembach, K. J. & Wetzel, G. D.: A novel monoclonal human IgM autoantibody which binds recombinant human and mouse tumor necrosis factor-alpha. Cell Immunol. 152: 556-568, 1993.
42. Brakenhoff, J. P., de-Hon, F. D., Fontaine, V., tenBoekel, E., Schooltink, H., Rose-John, S., Heinrich, P. C., Content, J. & Aarden, L. A.: Development of a human interleukin-6 receptor antagonist. J. Biol. Chem. 269: 86-93, 1994.
43. Brandt, S. J., Badine, D. M., Dunbar, C. E. & Nienhuis, A. W.: Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86: 592-599, 1990.
44. Bromander, A., Holmgren, J. & Lycke, N.: Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146: 2908-2914, 1991.
45. Campbell, I. L., Kay, T. W., Oxbrow, L. & Harrison, L. C.: Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87: 739-742, 1991.
46. Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D., Oldstone, M. B. & Mucke, L.: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA 90: 10061-10065, 1993.
47. Caruso, A., Bonfanli, C., Colombrita, D., DeFrancesco, M., De-Rango, C., Foresti, I., Gargiulo, F., Goniales, R., Gribaudo, G., Landolfo, S. et al.: Natural antibodies to IFN-gamma in man and their increase during viral infection. J. Immunol. 144: 685-690, 1990.
48. Castedo, M., Pelletier, L., Pasquier, R., Guettier, C., Huygen, K., Michel, J. B. & Drue t, P.: Anti-renin T cells trigger normal B cells to produce anti-renin antibodies and normalize blood pressure in spontaneously hypertensive rats. Int. Immunol. 5: 1569-1576, 1993.
49. Chadwick, D. E., Jean, L. F., Jamal, N., Messner, H. A., Murphy, J. R. & Minden, M. D.: Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein. Br. J. Haematol. 55: 25-36, 1993.
50. Chand, N., Harrison, J. E., Rooney, S., Pillar, J., Jakubicki, R., Nolan, K., Diamantis, IV. & Sofia, R. D.: Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach. Eur. J. Pharmacol. 211: 121-123, 1992.
51. Cheever, A. W., Finkelman, F. D., Caspar, P., Heiny, S., Macedonia, J. G. & Slier, A.: Treatment with anti-IL-2 antibodies reduces hepatic pathology and eosinophilia in Schistosoma mansoni-infected mice while selectively inhibiting T cell IL-5 production. J. Immunol. 148: 3244-3248, 1992.
52. Cheever, A. W., Williams, M. E., Wyim, T. A., Finkelman, F. D., Seder, R. A., Cox, T. M., Hieny, S., Caspar, P. & Slier, A.: Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J. Immunol. 155: 753-759, 1994.
53. Coffman, R. L., Seymour, B. W., Hudak, S., Jackson, J. & Rennick, D.: Antibody to interleukin-5 in-hibits helminth-induced eosinophilia in mice. Science 245: 308-310, 1989.
54. Cohen, S.: Cell mediated immunity and the inflammatory system. Hum. Pathol. 7: 249-264, 1976.
55. Conlon, K. C., Urba, W. J., Smith, J. W., Steis, R. G., Longo, D. L. & Clark, J. W.: Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65: 2237-2242, 1990.
56. Gasman, D.: The hematopoietin receptor superfamily. Cytokine 5: 95-106, 1993.
57. Crabtree, J. E., Peichl, P., Wyatt, J. I., Stachl, U. & Lindley, I. J.: Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand. J. Immunol. 37: 65-70, 1993.
58. De-Maeyer-Guignard, J., Cachard-Thomas, A. & DeMaeyer, E.: Naturally occurring anti-interferon antibodies in Lou/c rats. J. Immunol. 133: 775-778, 1984.
59. De-Maeyer-Guignard, J. & De-Maeyer, E.: Natural antibodies to interferon-alpha and interferon-beta are a common feature of inbred mouse strains. J. Immunol. 136: 1708-1711, 1986.
60. De-Saint-Pierre, V., Ehrhart, A., Baron, D., Plantin, P. & Le-Goff, P.: Systemic urticaria, sclerosing osteopathy, monoclonal gammopathy (Schnitzler syndrome). Apropos of a case. Rev. Rhum. Mal. Osteoartic 59: 288-292, 1992.
61. De-Togni, P., Goellner, J., Ruddle, N. H., S treeter, P. R., Pick, A., Mariathasan, S., Smith, S. C., Carlson, R., Shornick, L. P., Strauss-Schoenberger, J. et al.: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264: 703-707, 1994.
62. Debets, R. & Savelkoul, H. F. J.: Cytokine antagonists and their potential therapeutic use. Immunol. Today 75: 455-458, 1994.
63. Debray-Sachs, M., Carnaud, C., Boitard, C., Cohen, H., Gresser, I., Bedossa, P. & Bach, J. F.: Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J. Autoimmun. 4: 237-248, 1991.
64. Denis, M.: Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. J. Leukoc. Biol. 52: 197-201, 1992.
65. Derkx, B., Taminiau, J., Radema, S., Stronkhorst, A., Wortel, C., Tytgat, G. & Van Deventer, S.: Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 342: 173-174, 1993.
66. Diamant, M., Hansen, M. B., Rieneck, K., Svenson, M., Yasukawa, K. & Bendtzen, K.: Stimulation of the B9 hybridoma cell line by soluble Interleukin-6 receptors. J. Immunol. Methods 173: 229-235, 1994.
67. Dianzani, F., Antonelli, G., Amicucci, P., Cefaro, A. & Pintus, C.: Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. J. Interferon Res 9 Suppl 1: S33-S36, 1989.
68. Dinarello, C. A., Gelfand, J. A. & Wolff, S. M.: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269: 1829-1835, 1993.
69. Dinarello, C. A. & Wolff, S. M.: The role of interleukin-1 in disease. N. Engl. J. Med. 328: 106-113, 1993.
70. Dinarello, C. A.: Is there a role for interleukin-1 blockade in intravenous immunoglobulin therapy? Immunol. Rev. 739: 173-188, 1994.
71. Dillman, R. O.: Antibodies as cytotoxic therapy. J. Clin. Oncol. 12: 1497-1515, 1994.
72. Dummer, R., Muller, W., Nestle, F., Wiede, J., Dues, J., Lechner, W., Haubitz, L, Wolf, W., Bill, E. & Burg, G.: Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67: 2300-2304, 1991.
73. Dwyer, J. M.: Manipulating the immune system with immune globulin. N. Engl. J. Med. 526: 107-116, 1992.
74. Elliot, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C, Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, H. & Woody, J. N.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110, 1994a.
75. Elliot, M. J., Maini, R. N., Feldmann, AL, Long-Fox, A., Charles, P., Bijl, H. & Woody, J. N.: Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125-1127, 1994b.
76. Emilie, D., Widjenes, J., Gisselbrecht, C., Jarrousse, B., Billaud, E., Blay, J. Y., Gabarre, J., Gaillard, J. P., Brochier, J., Raphael, M., Boue, F. & Galanaud, P.: Administration of an anti-Interleukin6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 84: 2472-2479, 1994.
77. Escary, J. L., Perreau, J., Dumenil, D., Ezine, S. & Brulet, P.: Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 353: 361-364, 1993.
78. Fattori, E., Della Rocca, C., Costa, P., Giorgio, M., Dente, B., Pozzi, L. & Ciliberto, G.: Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83: 2570-2579, 1994.
79. Grau. G. E., Kindler, V., Piguet, P. F., Lambert, P. H. & Vassalli, P.: Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation. J. Exp. Med. 168: 1499-1504, 1988.
80. Grau, G. E., Heremans, H., Piguet, P. F., Pointaire, P., Lambert, P. H., Billiau, A. & Vassalli, P.: Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc. Natl. Acad. Sci. USA 86: 5572-5574, 1989.
81. Grau, G. E., Frei, K., Piguet, P. F., Fontana, A., Heremans, H., Billiau, A., Vassalli, P. & Lambert, P. H.: Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobulinemia. J. Exp. Med. 172: 1505-1508, 1990.
82. Gresser, I., Mauri, C., Tovey, G., Morel-Maroger, J. & Pontillon, J. C.: Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263: 420-422, 1976.
83. Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., McCafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones, N. C., et al.: Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12: 725-734, 1993.
84. Haak-Freudscho, M., Brown, J. F., lizawa, Y., Wagner, R. D. & Czuprynski, C. J.: Administration of anti-IL-4 monoclonal antibody 11B11 increases the resistance of mice to Listeria monocytogenes infection. J. Immunol. 148: 3978-3985, 1992.
85. Hakoda, H., Xie, Z. Q., Aizawa, H., Inoue, H., Hirata, M. & Ito, Y.: Effects of immunization against VIP on neurotransmission in cat trachea. Am. J. Physiol. 251: L341-L348, 1991.
86. Hanninen, E. L., Korfer, A., Hadam, M., Schneekloth, C., Dallmann, I., Menzel, T., Kirchner, H., Poliwoda, H. & Atzpodien, J.: Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res. 51: 6312-6316, 1991.
87. Hansen, M. B., Nielsen, S. E. & Berg, K.: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119: 203-210, 1989.
88. Hansen, M. B., Ross, C. & Berg, K.: A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J. Immunol. Methods 127: 241-248, 1990.
89. Hansen, M. B., Svenson, M. & Bendtzen, K.: Antiinterleukin-6 antibodies in normal human serum. Scand. J. Immunol. 33: 777-781, 1991b.
90. Hansen, M. B., Svenson, M. & Bendtzen, K.: Seruminduced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-α in normal human sera. Clin. Exp. Immunol. 88: 559-562, 1992.
91. Hansen, M. B., Svenson, M., Diamant, M. & Bendtzen, K.: High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5: 72-80, 1993.
92. Hansen, M. B., Svenson, M., Abell, K., Varming, K., Nielsen, H. P., Bertelsen, A. & Bendtzen, K.: Sex-and age-dependency of IgG auto-antibodies against IL-1α in healthy humans. Eur. J. Clin. Invest. 24: 212-218, 1994.
93. Hansen, M. B., Andersen, V., Rohde, K., Svenson, M., Florescn, A., Ross, C. & Bendtzen, K.: Cytokine autoantibodies in rheumatoid arthritis. Scand. J. Rheumatol. 24: 197-203, 1995a.
94. Hansen, M. B., Svenson, M., Abell, K., Yasukawa, K., Diamant, M. & Bendtzen, K.: Influence of Interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur. J. Immunol. 25: 348-354, 1995b.
95. Hansen, M. B., Svenson, M., Diamant, M., Ross, C. & Bendtzen, K.: IL-6 autoantibodies and blood IL-6 measurements. Blood 85: 1145, 1995c.
96. Harris, E. D. J.: Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322: 1277-1289, 1990.
97. Heimes, U., Jucker, W., Fischer, E. A., Krummenacher, T., Palleroni, A. V., Tromi, P. W., Linder-Ciccohmghi, S. & Rainisio, M.: The detection of antibodies to recombinant interferon alfa-2a in human serum. J. Biol. Stand. 15: 231-244, 1987.
98. Heremans, H., Van-Damme, J., Dillen, C., Dijkmans, R. & Billiaii, A.: Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartz-man-like shock reactions in mice. J. Exp. Med. 171: 1853-1869, 1990.
99. Heremans, H., Dillen, C., Put, W., Van-Damme, J. & Billiaii, A.: Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22: 2395-2401, 1992.
100. Hervë, P., Flescli, M., Tiberghien, P., Wijdenes, J., Racadot, E., Bordigoni, P., Plonvier, E., Stephan, J. L, Bonrdeaii, H. & Holler, E.: Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79: 3362-3368, 1992.
101. Hestdal, K., Jacobsen, S. E., Ruscetti, F. W., Dubais, C. M., Longo, D. L., Chizzonite, R., Oppenheim, J. J. & Keller, J. R.: In vivo effect of interleukin-I alpha on hematopoiesis: role of colony-stimulating factor receptor modulation. Blood 80: 2486-2494, 1992.
102. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T. & Kishimoto, T.: Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149-1157, 1990.
103. Hill, R. J., Warren, M. K., Stenberg, P., Levin, J., Corasli, L., Drummond, R., Baker, G., Levin, F. & Mok, Y.: Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood 77: 42-48, 1991.
104. Hirauo, T., Akira, S., Taga, T. & Kishimoto, T.: Biological and clinical aspects of interleukin 6. Immunol. Today 11: 443-449, 1990.
105. Horii, Y., Muraguchi, A., Iwano, M., Matsuda, T., Hirayama, T., Yamada, H., Fujii, Y., Dohi, K., Ishikawa, H., Ohmoto, Y., et al.: Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol. 143: 3949-3955, 1989.
106. Ip, N. Y. & Yancopoulos, G. D.: Neurotrophic factors and their receptors. Ann. Neurol. 35 Suppl: SI 3-S16, 1994.
107. Ishizaka, S. & Tsujii, T.: IL-2 antibody production in lupus mice. Cell Immunol. 118: 100-107, 1989.
108. Issekutz, A. C., Meager, A. , Otterness, I. & Issekutz, T. B.: The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin. Exp. Immunol. 97: 26-32, 1994.
109. Itri, L. M., Campion, M., Dennin, R. A., Palleroni, A. V., Gutterman, J. U., Groopman, J. E. & Trown, P. W.: Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 59: 668-671, 1987.
110. Itri, L. M., Sherman, M. L, Palleroni, A. V., Evans, L. M., Tran, L. L., Campion, M. & Chizzonite, R.: Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. J. Interferon Res. 9 Suppl 1: S9-15, 1989.
111. Iverson, B. L. & Lerner, L. R.: Sequence-specific peptide cleavage catalyzed by an antibody. Science 243: 1184-1188, 1989.
112. Janeway, C. A. J. & Bottomly, K.: Signals and signs for lymphocyte responses. Cell 76: 275-285, 1994.
113. Jeffes, E., Ininns, E., Schmilz, K., Yamamoto, R., Den, C. & Granger, G.: The presence of antibodies to lymphotoxin and tumor necrosis factor in normal serum. Arthritis Rheum. 32: 1148-1152, 1989.
114. Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H. & Manolagas, S. C.: Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257: 88-91, 1992.
115. Jourdan, M., Bataille, R., Seguin, J., Zhang, X. G., Chaptal, P. A. & Klein, B.: Constitutive production of interleukin-6 and immunologie features in cardiac myxomas. Arthritis Rheum. 33: 398-402, 1990.
116. Kanagawa, O., Vaupel, B. A., Gayama, S., Koehler, G. & Kopf, M.: Resistance of mice deficient in IL-4 to retrovirus-induced immunodeficiency syndrome (MAIDS). Science 262: 240-242, 1993.
117. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al.: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988.
118. Kay, T. W., Campbell, I. L.. Oxbrow. L. & Harrison, L. C.: Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-gamma antibody. Diabetologia 34: 779-785, 1991.
119. Kirchner, H., Körfer, A., Evers, P., Szaine,l M. M., Knüver-Hopf, J., Mohr, H., Franks, C. R., Pohl, U., Resch, K., Hadam, M., Poliwoda, H. &Atzpodien, J.: The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural Interleukin-2. Cancer 67: 1862-1864, 1991.
120. Kishimoto, T., Akira, S. & Taga, T.: Interleukin-6 and its receptor: a paradigm for cytokines. Science 258: 593-597, 1992.
121. Kishimoto, T., Taga, T. & Akira, S.: Cytokine signal transduction. Cell 76: 253-262, 1994.
122. Klein, B., Wijdenes, J., Zhang, X. G., Jourdan, M., Boiron, J. M., Brocliier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fonrnier, B., et al.: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198-1204, 1991.
123. Kondo, M., Takeshita, T., Hignchi, M., Nakamura, M., Sudo, T., Nishikawa, S. & Sitgamura, K.: Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 263: 1453-1454, 1994.
124. Kopf, M., Banmann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bhiethmann, H. & Kohler, G.: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342, 1994.
125. Kreitman, R. J., Siegall, C. B., FitzGerald, D. J., Epstein, J., Barlogie, B. & Past an, L: Interleukin6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 79: 1775-1780, 1992.
126. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. & Midier, W.: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
127. Kundig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkernagel, R. M. & Horak, L: Immune responses in interleukin-2-deficient mice. Science 262: 1059-1061, 1993.
128. Larner, A. C., David, M., Feldman, G. M., Igarashi, K., Hackett, R. H., Webb, D. S., Sweitzer, S. M., Petricoin, E. F. & Finbloom, D. S.: Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 267: 1730-1733, 1993.
129. Larocca, A. P., Leung, S. C., Marcus, S. G., Colby, C. B. & Borden, E. C.: Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J. Interferon. Res. 9 Suppl 1: S51-S60, 1989.
130. Leger-Ravet, M. B., Peuchmaur, M., Devergne, O., Audouin, J., Raphael, M., Van-Damme, J., Galanaud, P., Diebold, J. & Emilie, D.: Interleukin-6 gene expression in Castleman's disease. Blood 78: 2923-2930, 1991.
131. Leusch, H. G., Sitzler, G. & Markos-Pusztai, S.: Failure to demonstrate TNFα-specific autoantibodies in human sera by ELISA and Western blot. J. Immunol. Methods 139: 145-147, 1991.
132. Lewis, D. B., Liggitt, H. D., Effmann, E. L., Motley, S. T., Teitelbaum, S. L., Jepsen, K. J., Goldstein, S. A., Bonadio, J., Carpenter, J. & Perlmutter, R. M.: Osteoporosis induced in mice by overproduction of interleukin 4. Proc. Natl. Acad. Sci. U S A 90: 11618-11622, 1993.
133. Lok, A. S., Lai, C. L. & Leung, E. K.: Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12: 1266-1270, 1990.
134. Lu, Z. Y., Brochier. J., Wijdenes, J., Brailly, H., Bataille, R. & Klein, B.: High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22: 2819-2824, 1992.
135. Lutticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al.: Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263: 89-92, 1994.
136. Mae, N., Liberato, D. J., Chizzonite, R. & Satoh, H.: Identification of high-affinity anti-IL-1 alpha autoantibodies in normal human serum as an interfering substance in a sensitive enzyme-linked immunosorbent assay for IL-1 alpha. Lymphokine Cytokine Res. 10: 61-68, 1991.
137. Maes, M., Stevens, W., Scharp', S., Bosmans, E., De Meyer, F., D'Hondt, P., Peeters, D., Thompsom, P., Cosyns, P., De Clerck, L., Bridts, C., Neels, H., Wauters, A. & Cooreman, W.: Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble intedeukin-2 and -6 receptor concentrations in normal volunteers. Experientia 50: 821-829, 1994.
138. Martens, E., Dillen, C., Put, IV., Heremans, H., VanDamme, J. & Billion, A.: Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes. Eur. J. Immunol. 23: 2026-2029, 1993.
139. Matsiota, P., Saron, M. F., Guillon, J. C. & Avrameas, S.: Mouse natural autoantibodies can interfere with murine alpha and beta interferons. J. Virol. 63: 955-956, 1989.
140. May, L. T., Viguet, H., Kenney, J. S., Ida, N.. Allison, A. C. & Sehgal, P. B.: High levels of 'complexed' interleukin-6 in human blood. J. Biol. Chem. 267: 19698-19704, 1992.
141. May, L. T., Neta, R., Moldauer, L. L., Kenney, J. S., Patel, K. & Sehgal, P. B.: Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J. Immunol. 151: 3225-3236, 1993.
142. McCune, C. S. & Marquis, D. M.: Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res. 50: 1212-1215, 1990.
143. Miliara, M., Koishihara, Y., Fukni, H., Yasukawa, K. & Ohsugi, Y.: Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 74: 55-59, 1991.
144. Mogensen, K. E., Daubas, P. H., Gresser, I., Serini, D. & Varet, B.: Patient with circulating antibodies to α-Interferon. Lancet ii: 1227-1228, 1981.
145. Montero-Julian, F. A., Klein, B., Gautherot, E. & Brailly, H.: Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: Enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 85: 917-924, 1995.
146. Monti, E., Pozzi, A., Tiberio, L., Morelli, D., Caruso, A., Villa, M. L. & Balsari, A.: Purification of interleukin-2 antibodies from healthy individuals. Immunol. Lett. 36: 261-266, 1993.
147. Montminy, M.: Trying on a new pair of SH2s. Science 261: 1694-1695, 1993.
148. Mosmann, T.: A rapid colorimetric assay for cellular growth and cytotoxicity. J. Immunol. Methods. 65: 55-63, 1983.
149. Mulligan, M. S., Jones, M. L., Bolanowski, M. A., Baganoff, M. P., Deppeier, C. L., Meyers, D. M., Ryan, U. S. & Ward, P. A.: Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J. Immunol. 150: 5585-5595, 1993.
150. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koisliiliara, Y., Yancopoulos, G. D., Taga, T. & Kishimoto, T.: Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126, 1993.
151. Neurath, A. R., Strick, N. & Li, Y. Y.: Cells transfected with human interleukin 6 cDNA acquire binding sites for the hepatitis B virus envelope protein. J. Exp. Med. 176: 1561-1569, 1992.
152. Nichols, P. H., Ramsden, C. W., Ward, U., Trejdosiewicz, L. K., Ambrose, N. S. & Primrose, J. N.: Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin. Exp. Immunol. 94: 4-10, 1993.
153. Nicoletti, F., Meroni, P. L., Landolfo, S., Garglio, M., Guzzardi, S., Barcellini, W., Lunetta, M., Mughi-ni, L. & Zanussi, C.: Prevention of diabetes in BB/ Wor rats treated with monclonal antibodies to interferon-γ. Lancet 536: 319, 1990.
154. Nognchi, M., Yi, H., Rosenblatt, H. M., Filipovich, A. H., Adelstein, S., Modi, W. S., McBride, O. W. & Leonard, W. J.: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147-157, 1993.
155. Nossal, G. J.: Negative selection of lymphocytes. Cell 76: 229-239, 1994.
156. Ohlsson, K., Bjork, P., Bergenfehlt, M., Hageman, R. & Thompson, R. C.: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550-552, 1990.
157. Oldenburg, H. S., Rogy, M. A., Lazarus, D. D., VanZee, K. J., Keeler, B. P., Chizzonite. R. A., Lowry, S. F. & Moldawer, L. L.: Cachexia and the acutephase protein response in inflammation are regulated by interleukin-6. Eur. J. Immunol. 23: 1889-1894, 1993.
158. Oldstone, M. B.: Molecular mimicry and autoimmune disease. Cell 50: 819-820, 1987.
159. Palleroni, A. V. & Trown, P. W.: A sensitive radioimmunoassay for detection of antibodies to recombinant human interferon-alpha A. J. Interferon. Res. 6: 705-712, 1986.
160. Panem, S., Check, I. J., Henriksen, D. & Vilcek, J.: Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129: 1-3, 1982.
161. Panem, S.: Interferon. Vol. 2. Interferons and the immune system. Antibodies to interferon in man, Amsterdam.: Elsevier, 1984.
162. Paul, S., H-Erian, P. & Said, S. I.: Human autoantibody to vasoactive intestinal peptide in human circulation. Biochemical and Biophysical Research Communications 130: 479-485, 1985.
163. Paul, S., Johnson, D. R. & Massey, R.: Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies. Ciba Found Symp. 159: 156-167; discus, 1991a.
164. Paul, S., Mei, S., Mody, B., Eklund, S. H., Beach, C. M., Massey, R. J. & Hamel, F.: Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies. J. Biol. Chem. 266: 16128-16134, 1991b.
165. Paul, W. E. & Seder, R. A.: Lymphocyte responses and cytokines. Cell 76: 241-251, 1994.
166. Pearse, A.: Histochemistry. Theoretical and applied, London: J. & A: Churchill, Ltd, 1960.
167. Pedersen, M., Permin, J.J., Bindslev-Jensen, C., Bendtzen, K. & Norn,
168. Peichl, P., Ceska, M., Broell, J., Effenberger, F. & Lindley, I. J.: Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis. Ann. Rheum. Dis. 51: 19-22.
169. Portier, M., Lees, D., Caron, E., Jourdan, M., Boiron, J. M., Bataille, R. & Klein, B,: Up-regulation of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. FEBS Lett. 302: 35-38, 1992.
170. Portier, M., Zhang, X. G., Caron, E., Lu, Z. Y., Bataille, R. & Klein, B.: gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 81: 3076-3082, 1993.
171. Pozzetto, B., Mogensen, K. E., Tovey, M. G. & Gresser, I.: Characteristics of autoantibodies to human Interferon in a patient with varicella-zoster disease. J. Infect. Dis. 750: 707-713, 1984.
172. Prümmer, O., Seyfarth, C., Sclierbawn, W. A., Drees, N. & Porzsolt, F.: Interferon-α antibodies in autoimmune diseases. J. Interferon. Res. 9, Suppl. 1: S67-S74, 1989.
173. Prümmer, O., Frickhofen, N., Digel, W., Heimpel, H. & Porzsolt, F.: Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann. Hematol. 62: 76-80, 1991.
174. Prümmer, O.: Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 71: 1828-1834, 1993.
175. Prümmer, O., Streichan, U., Heimpel, H. & Porzsolt, F.: Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies. J. Immunol. Methods. 171: 45-53, 1994.
176. Puck, J. M.: Molecular and genetic basis of X-linked immunodeficiency disorders. J. Clin. Immunol. 14: 81-89, 1994.
177. Ramirez, F., Williams, R. C. J., Sibbitt, W. L. J. & Searles, R. P.: Immunoglobulin from systemic lupus erythematosus serum induces interferon release by normal mononuclear cells. Arthritis Rheum. 29: 326-336, 1986.
178. Ramsay, A. J., Husband, A. J., Ramshaw, I. A., Bao, S., Matthaei, K. I., Koehler, G. & Kopf, M.: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264: 561-563, 1994.
179. Rich, B. E., Campos-Torres, J., Tepper, R. I., Morcadith, R. W. & Leder, P.: Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J. Exp. Med. 177: 305-316, 1993.
180. Ross, C., Hansen, M. B., Schyberg, T. & Berg, K.: Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin. Exp. Immunol. 82: 57-62, 1990.
181. Ross, C., Svenson, M., Hansen, M. B., Vejlsgaard, G. & Bendtzen, K.: High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 95: 1974-1978, 1995.
182. Ruddle, N. H., Bergman, C. M., McGrath, K. M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J. & Clark, R. B.: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 772: 1193-1200, 1990.
183. Ryffel, B., Kammuller, M., Robison, R. & Myers, L.: Pathology induced by interleukin-6. Toxicol. Lett. 64-65 Spec. No: 311-319, 1992.
184. Ryffel, B., Car, B. D., Woerly, G., Weber, M., DiPadova, F., Kammuller, M., Klug, S., Neubert, R. & Neubert, D.: Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate the marmoset. Blood 83: 2093-2102, 1994.
185. Sadick, M. D., Heinzel, F. P., Holaday, B. J., Pu, R. T., Dawkins, R. S. & Locksky, R. M.: Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171: 115-127, 1990.
186. Sadowski, H. B., Shuai, K., Darnell, J. E. J. & Gilman, M. Z.: A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 261: 1739-1744, 1993.
187. Sarna, G. P., Figlin, R. A., Pertcheck, M., Altrock, B. & Kradjian, S. A.: Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. J. Biol. Response Mod. 8: 16-24, 1989.
188. Sato, K., Tsuchiya, M., Saldanha, J., Koishihara, Y., Ohsitgi, Y., Kishimoto, T. & Bendig, M. M.: Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol. Immunol. 31: 371-381, 1994.
189. Saurat, J. H., Schifferli, J., Steiger, G., Dayer, J. M. & Didierjean, L.: Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution, and receptor-binding inhibition - higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia). J. Allergy Clin. Immunol. 88: 244-256, 1991.
190. Savino, R., Lahm, A., Sahati, A. L., Ciapponi, L., Sporeno, E., Altamura, S., Paonessa, G., Toniatti, C. & Ciliberto, G.: Generation of interleukin-6 antagonists by molecular-modeling guided mutagenesis of residues important for gp 130 activation. EMBO J. 13: 1357-1367, 1994.
191. Scheid, C., Young, R., McDermott, R., Fitzsimmons, L., Scarffe, J. H. & Stern, P. L.: Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunother. 38: 119-126, 1994.
192. Schwimmbeck, P. L., Yu, D. T. & Oldstone, M. B.: Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J. Exp. Med. 166: 173-181, 1987.
193. Sedmak, J. J. & Grossberg, S. E.: High levels of circulating neutralizing antibody in normal animals to recombinant mouse interferon-beta produced in yeast. J. Interferon. Res. 9 Suppl 1: S61-S65, 1989.
194. Sheehan, K. C, Ruddle, N. H. & Schreiber, R. D.: Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 142: 3884-3893, 1989.
195. Shirai, A., Holmes, K. & Klinman, D.: Detection and quantitation of cells secreting IL-6 under physiologic conditions in BALB/c mice. J. Immunol. 150: 793-799, 1993.
196. Sibbitt, W. L. J., Gibbs, D. L., Kenny, C., Bankhurst, A. D., Searles, R. P. & Ley, K. D.: Relationship between circulating interferon and anti-interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus. Arthritis Rheum. 28: 624-629, 1985.
197. Siegall, C. B., Kreitman, R. J., FitzGerald, D. J. & Pastan, I.: Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res. 57: 2831-2836, 1991.
198. Smith, J. W., Longo, D. L, Urba, W. J., Clark, J. W., Watson, T., Beveridge, J., Conlon, K. C., Sznol, M., Creekmore, S. P., Ahord, W. G., et al.: Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood 78: 1664-1671, 1991.
199. Smith, J. W., Longo, D. L., Ahord, W. G., Janik, J. E., Sharfman, W. H., Gause, B. L., Curti, B. D., Creekmore, S. P., Holmhmd, J. T. & Pent on, R. G., et al.: The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N. Engl. J. Med. 328: 756-761, 1993.
200. Spiegel, J., Spicehandler, J. R., Jacobs, S. L. & Odern, E. M.: Low incidence of serum neutralizing factors in patients recieving recombinant alpha 2b interferon (Intron A). Am. J. Med. 80: 223-228, 1986.
201. Spiegel, R. J., Jacobs, S. L. & Treuhaft, M. W.: Antiinterferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J. Interferon Res. 9 Suppl 1: S17-S24, 1989.
202. Stahl, N., Boulton, T. G., Farruggella, T., Ip, N. Y., Davis, S., Winhulm, B. A., Quelle, F. W., Silvenuoinen, O., Barbieri, G., Pellegrini, S., et al.: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263: 92-95, 1994.
203. Stanley, E., Lieschke, G. J., Grail, D., Metcalf, D., Hodgson, G., Gall, J. A., Maher, D. W., Cebon, J., Sinickas, V. & Dunn, A. R.: Granulocyte/ macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA 91: 5592-5596, 1994.
204. Starnes, H. F. J., Pearce, M. K., Tewari, A., Yim, J. H., Zou, J. C. & Abrams, J. S.: Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J. Immunol. 145: 4185-4191, 1990.
205. Starnes, H. F., Pearce, M., Yim, J., Abrams, J., Tewari, A. & Zou, J.: Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge ' in mice [retraction of Starnes, H. F. Jr., Pearce, M. K., Tewari, A., Yim, J. H., Zou, J. C. & Abrams, J. S. In: J Immunol 1990 Dec 15;145(12): 4185-91]. J. Immunol. 148: 1968, 1992.
206. Steis, R. G., Smith, J. W., Urba, W. J., Clark, J. IV., Itri, L. M., Evans, L. M., Schoenberger. C. & Longo, D. L.: Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318: 1409-1413, 1988.
207. Steis, R. G., Smith, J. W., Urba, W. J., Venzon, D. J., Longo, D. L., Barney, R., Evans, L. M., Itri, L. M. & Ewel, C. H.: Loss of interferon antibodies during prolonged continuous interferonalpha 2a therapy in hairy cell leukemia. Blood 77: 792-798, 1991.
208. Strassmann, G., Fong, M., Kenney, J. S. & Jacob, C. O.: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89: 1681-1684, 1992.
209. Strassmann, G., Fong, M., Freter, C. E., Windsor, S., D'Alessandro, F. & Nordan, R. P.: Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Invest. 92: 2152-2159, 1993.
210. Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T. & Kishimoto, T.: IgGl plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA 86: 7547-7551, 1989.
211. Suematsu, S., Matsusaka, T., Matsuda, T., Ohno, S., Miyaiaki, J., Yamamura, K., Hirano, T. & Kishimoto, T.: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA 89: 232-235, 1992.
212. Suit, B. E., Axelrod, D., Moutsopoiilos, H. M., Decker, J. L. & Hooks, J. J.: Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin. Exp. Rheumatol. 1: 133-135, 1983.
213. Sunder-Plassmann, G., Sedlacek, P. L., Sunder-Plassmann, R., Derfler, K., Swoboda, K., Fabrizii, V., Hirschl, M. M. & Balcke, P.: Anti-interleukin-1 alpha autoantibodies in hemodialysis patients. Kidney Int. 40: 787-791, 1991.
214. Sunder-Plassmann, G., Kapiotis, S., Gasche, C., Klaar, U. & Mai, B.: Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int. 45: 1484-1488, 1994.
215. Suzuki, H., Akama, T., Okane, M., Kono, I., Matsui, Y., Yamane, K. & Kashiwagi, H.: Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum. 32: 1528-1538, 1989.
216. Suzuki, H., Kaminmra, J., Ayabe, T. & Kashiwagi, H.: Demonstration of neutralizing autoantibodies against IL-1 alpha in sera from patients with rheumatoid arthritis. J. Immunol. 145: 2140-2146, 1990.
217. Suzuki, H., Ayabe, T., Kamimura, J. & Kashiwagi, H.: Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin. Exp. Immunol. 85: 407-412, 1991.
218. Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T. & Kishimoto, T.: Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol. 22: 1989-1993, 1992.
219. Suzuki, H., Takemura, H., Yoshizaki, K., Koishihara, Y., Ohsugi, Y., Okano, A., Akiyama, Y., Tojo, .T, Kishimoto, T. & Kashiwagi, H.: IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J. Immunol. 152: 935-942, 1994.
220. Suzuki, Y., Yang, Q., Conley, F. K., Abrams, J. S. & Remington, J. S.: Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect. Immun. 62: 2773-2778, 1994.
221. Svenson, M., Poulsen, L. K., Fomsgaard, A. & Bendtzen, K.: IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand. J. Immunol. 29: 489-492, 1989.
222. Svenson, M., Bagge-Hansen, M. & Bendtzen, K.: Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera. Scand. J. Immunol. 32: 695-701.
223. Svenson, M., Hansen, M. B., Kayser, L., Rasmussen, A. K., Reimert, C. M. & Bendtzen, K.: Effects of human anti-IL-1 alpha autoantibodies on receptor binding and biological activities of IL-1. Cytokine 4: 125-133, 1992.
224. Svenson, M., Hansen, M. B. & Bendtzen, K.: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92: 2533-2539, 1993a.
225. Svenson, M., Hansen, M. B., Heegaard, P., Abell, K. & Bendtzen, K.: Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-Ira) to human serum. High-affinity binding of IL-Ira to soluble IL-1 receptor type I. Cytokine 5: 427-435, 1993b.
226. Sylvester. I., Yoshimura, T., Sticherling, M., Schroder, J. M., Ceska, M., Peichl, P. & Leonard, E. J.: Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 anti-body in normal human serum. J. Clin. Invest. 90: 471-481, 1992.
227. Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T. & Kishimoto, T.: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58: 573-581, 1989.
228. Takemura, H., Suzuki, H., Yoshizaki, K., Ogata, A., Ynhara, T., Akama, T., Yaniane, K. & Kashiwagi, H.: Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum. 35; 940-943, 1992.
229. Tang, H., Mignon-Godefroy, K., Meroni, P. L., Garotta, G., Charreire, J. & Nicoletti, F.: The effects of a monoclonal antibody to interferon-γ on experimental autoimmune thyroiditis (EAT): Prevention of disease and decrease of EAT-specific T cells. Eur. J. Immunol. 23: 275-278, 1993.
230. Tiberio, L., Caruso, A., Pozzi, A., Rivoltini, L., Morelli, D., Monti, E. & Balsari, A.: The detection and biological activity of human antibodies to IL-2 in normal donors. Scand. J. Immunol. 38: 472-476, 1993.
231. Trown, P. W., Kramer, M. J., Dennin, R. A. J., Counell, E. F., Palleroni, A. V., Quesada, J. & Gutternmn, J. U.: Antibodies to human leucocyte interferons in cancer patients. Lancet J: 81-84, 1983.
232. Turano, A., Balsari, A., Viani, E., Landolfo, S., Zanoni, L., Gargiulo, F. & Caruso, A.: Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. Proc. Natl. Acad. Sci. USA 89: 4447-4451, 1992.
233. Turksen, K., Kupper, T., Degenstein, L., Williams, I. & Fuchs, E.: Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc. Natl. Acad. Sci. USA 59: 5068-5072, 1992.
234. Umland, S. P., Razac, S., Nahrebne, D. K. & Seymour, B. W.: Effects of in vivo administration of interferon (IFN)-gamma, anti-IFN-gamma, or anti-interleukin-4 monoclonal antibodies in chronic autoimmune graft-versus-host disease. Clin. Immunol. Immunopathol. 63: 66-73, 1992.
235. Vallbracht, A., Treuner, J., Flehmig, B., Joester, K. E. & Niethammer, D.: Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289: 496-497, 1981.
236. Vallbracht, A., Treuner, J., Mannckc, K. H. & Niethammer, D.: Autoantibodies against human beta interferon following treatment with interferon. J. Interferon Res. 2: 107-110, 1982.
237. van-den-Berg, W. B., Joosten, L. A., Helsen, M. & van-de-Loo, F. A.: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95: 237-243, 1994.
238. van-der-Poll, T., Levi, M., Hack, C. E., ten-Cate, H., van-Deventer, S. J., Eerenberg, A. J., DeGroot, E. R., Jansen, J., Gallati, H., Buller, H. R., et al.: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 179: 1253-1259, 1994.
239. van-Gameren, M. M., Willemse, P. H. B., Mulder, N. H., Limburg, P. C., Groen, H. J. M., Vellenga, E. & de Vries, E. G. E.: Effects of recombinant human interelukin-6 in cancer patients: A phase I-II study. Blood 84: 1434-1441, 1994.
240. van-Snick, J.: Interleukin-6: an overview. Annu. Rev. Immunol. 8: 253-278, 1990.
241. Viani, E., Flamminio, G., Caruso, A., Forest!, I., DeFrancesco, M., Pollara, P., Balsari, A. & Turano, A.: Purification of natural human IFN-gamma antibodies. Immunol. Lett. 30: 53-58, 1991.
242. Vink, A., Coulie, P., Warnier, G., Renauld, J. C., Stevens, M., Donckers, D. & Van-Snick, J.: Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 172: 997-1000, 1990.
243. von Wussow, P., Freund, M., Block, B., Diedrich, H., Poliwoda, H. & Deicher, H.: Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet 2: 635-636, 1987.
244. von Wussow, P., Freund, M., Dahle, S., Jakschies, D., Poliwode, H. & Deicher, H.: Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N. Engl. J. Med. 379: 1226-1227, 1988a.
245. von Wussow, P., Hartmann, F., Freund, M., Poliwoda, H. & Deicher, H.: Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b. Lancet 1: 882-883, 1988b.
246. von Wussow, P., Jakschies, D., Freund, M. & Deicher, H.: Humoral response to recombinant interferonalpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J. Interferon Res. 9 Suppl 1: S25-S31, 1989.
247. von Wussow, P., Jakschies, D., Freund, M., Hehlmann, R., Brockhaus, F., Hochkeppel, H., Horisberger, M. & Deicher, H.: Treatment of antirecombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Br. J. Haematol. 78: 210-216, 1991.
248. Weck, P. K., Leventhal, B. G., Brand, C. & Finter, N. B.: Detection and incidence of neutralizing anti-bodies to interferon-alpha-no. J. Interferon Res. 9 Suppl 1: S37-S43, 1989.
249. Weisdorf, D., Katsanis, E., Verfaillie, C., Ramsay, N. K. C., Haake. R., Garrison, L. & Blazar, B. R.: Interelukin-la administered after autologous transplantation: A phase I/II clinical trial. Blood 84: 2044-2049, 1994.
250. Wendling, D., Racadot, E. & Wijdenes, J.: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20: 259-262, 1993.
251. WHO.: WHO expert commitee on biological standardization. Thirty-fith report, Geneva.: WHO Technical report series 687-725, 1985.
252. Wilkin, T. J.: Receptor autoimmunity in endocrine disorders. N. Engl. J. Med. 325: 1318-1324, 1990.
253. Wilkin, T. J., Voss, L., Tuck, A., Bullen, H. & Betts, P.: Autoantibodies to endogenous growth hormone in short children (the Wessex Growth Study). Autoimmunity 14: 67-72, 1992.
254. Wohlrab, F., Seidler, E. & Kunze, K.: Histo- und Zytochemie dehydriender Enzyme, Leipzig: Johann Ambrosius Barth, 1979.
255. Woodroofe, C., Muller, W. & Ruther, U.: Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 11: 587-592, 1992.
256. Yoneda, T., Nakai, M., Moriyama, K., Scott, L., Ida, N., Kwnitomo, T. & Mundy, G. R.: Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res. 53: 737-740, 1993.
257. Öberg, K. & Alm, G. V.: Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J. Interferon Res. 9 Suppl 1: S45-S49, 1989.
258. Öberg, K., Alm, G., Magnusson, A., Lundqvist, G., Theodorsson, E., Wide, L. & Wilander, E,: Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl. Cancer Inst. 81: 531-535, 1989.